NCT02481830COMPLETEDanonymous

An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)

Sponsor

Source record

Bristol-Myers Squibb

Phase

Source record

PHASE3

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Nivolumab, Topotecan, Amrubicin

Indication / condition

AI-normalized

Lung Cancer

Intervention

Source record

Nivolumab, Topotecan, Amrubicin

Source & freshness

Source record

NCT ID

NCT02481830

Original source

ClinicalTrials.gov

Source last updated

Jul 27, 2023

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT02481830

Title

An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)

Sponsor

Bristol-Myers Squibb

Status

COMPLETED

Phase

PHASE3

Condition raw

Lung Cancer

Condition normalized

Lung Cancer

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Nivolumab, Topotecan, Amrubicin

Target normalized

Nivolumab, Topotecan, Amrubicin

Interventions

Nivolumab, Topotecan, Amrubicin

Public preview

Source record

The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02481830

Status

COMPLETED

Phase

PHASE3

Sponsor

Bristol-Myers Squibb

Executive brief

Investment-Ready Snapshot

The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJul 27, 2023

Internal syncJun 09, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02481830

Indication

Lung Cancer

Modality

monoclonal antibody

Target

Nivolumab, Topotecan, Amrubicin

Intervention

Nivolumab, Topotecan, Amrubicin

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.